2020-03-11 最新期刊文獻

-
本日新增48篇文獻。南韓CDC分享利用就醫紀錄、手機GPS、信用卡紀錄和CCTV監視器等追蹤接觸者的經驗和優缺點(9)。在治療方面，北京學者認為CEP、selamectin 和 mefloquine hydrochloride為治療新冠肺炎的可能藥物(14)。

  1. Al-Tawfiq JA & Memish ZA. (2020). Diagnosis of SARS-CoV-2 Infection based on CT scan vs. RT-PCR: Reflecting on Experience from MERS-CoV.  Journal of Hospital Infection, doi:10.1016/j.jhin.2020.03.001, https://doi.org/10.1016/j.jhin.2020.03.001 
  2. Biondi-Zoccai G, Landoni G, Carnevale R, Cavarretta E, Sciarretta S & Frati G. (2020). SARS-CoV-2 and COVID-19: facing the pandemic together as citizens and cardiovascular practitioners.  Minerva Cardioangiologica, doi:10.23736/S0026-4725.20.05250-0, https://doi.org/10.23736/S0026-4725.20.05250-0 
  3. Calisher C, Carroll D, Colwell R, Corley RB, Daszak P, Drosten C, et al. (2020). Statement in support of the scientists, public health professionals, and medical professionals of China combatting COVID-19.  Lancet, 395, e42-e43. doi:10.1016/S0140-6736(20)30418-9, https://doi.org/10.1016/S0140-6736(20)30418-9 
  4. Carvalho PMM, Moreira MM, de Oliveira MNA, Landim JMM & Neto MLR. (2020). The psychiatric impact of the novel coronavirus outbreak.  Psychiatry Research, 286, 112902. doi:10.1016/j.psychres.2020.112902, https://doi.org/10.1016/j.psychres.2020.112902 
  5. Chen D, Xu W, Lei Z, Huang Z, Liu J, Gao Z, et al. (2020). Recurrence of positive SARS-CoV-2 RNA in COVID-19: A case report.  International Journal of Infectious Diseases, doi:10.1016/j.ijid.2020.03.003, https://doi.org/10.1016/j.ijid.2020.03.003 
  6. Chen Z, Xiong H, Li JX, Li H, Tao F, Yang YT, et al. (2020). 兒童白血病化療後粒細胞缺乏合併新型冠狀病毒（COVID-19）肺炎一例 [COVID-19 with post-chemotherapy agranulocytosis in childhood acute leukemia: a case report].  Chung-Hua Hsueh Yeh Hsueh Tsa Chih: Chinese Journal of Hematology, 41, E004. doi:10.3760/cma.j.issn.0253-2727.2020.0004, https://doi.org/10.3760/cma.j.issn.0253-2727.2020.0004 
  7. Cheng AC & Williamson DA. (2020). An outbreak of COVID-19 caused by a new coronavirus: what we know so far.  Medical Journal of Australia, doi:10.5694/mja2.50530, https://doi.org/10.5694/mja2.50530 
  8. Cho HW. (2020). Effectiveness for the Response to COVID-19: The MERS Outbreak Containment Procedures.  Osong Public Health & Research Perspectives, 11, 1-2. doi:10.24171/j.phrp.2020.11.1.01, https://doi.org/10.24171/j.phrp.2020.11.1.01 
  9. COVID-19 National Emergency Response Center, Epidemiology & Case Management Team, Korea Centers for Disease Control & Prevention. (2020). Contact Transmission of COVID-19 in South Korea: Novel Investigation Techniques for Tracing Contacts.  Osong Public Health & Research Perspectives, 11, 60-63. doi:10.24171/j.phrp.2020.11.1.09, https://doi.org/10.24171/j.phrp.2020.11.1.09 
  10. COVID-19 National Emergency Response Center, Epidemiology and Case Management Team, Korea Centers for Disease Control and Prevention. (2020). Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea.  Osong Public Health & Research Perspectives, 11, 8-14. doi:10.24171/j.phrp.2020.11.1.03, https://doi.org/10.24171/j.phrp.2020.11.1.03 
  11. Dai MD & Cheng L. (2020).呼吸道冠狀病毒感染的臨床特徵以及與耳鼻咽喉科的關聯 [Clinical features of respiratory coronavirus infections and relationship to otolaryngology].  Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi = Chinese Journal of Otorhinolaryngology Head & Neck Surgery, 55, E002. doi:10.3760/cma.j.cn115330-20200227-00135,  http://rs.yiigle.com/yufabiao/1184373.htm
  12. Dodd RY & Stramer SL. (2020). COVID-19 and Blood Safety: Help with a Dilemma.  Transfusion Medicine Reviews, doi:10.1016/j.tmrv.2020.02.004, https://doi.org/10.1016/j.tmrv.2020.02.004 
  13. Dong L, Hu S & Gao J. (2020). Discovering drugs to treat coronavirus disease 2019 (COVID-19).  Drug Discoveries & Therapeutics, 14, 58-60. doi:10.5582/ddt.2020.01012, https://doi.org/10.5582/ddt.2020.01012 
  14. Fan HH, Wang LQ, Liu WL, An XP, Liu ZD, He XQ, et al. (2020). Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus (2019-nCoV) related coronavirus model.  Chinese Medical Journal, doi:10.1097/CM9.0000000000000797, https://doi.org/10.1097/CM9.0000000000000797 
  15. Guan Q, Liu M, Zhuang YJ, Yuan Y, Wang SS, Li J, et al. (2020). 一起新型冠狀病毒肺炎家族聚集性疫情流行病學調查分析 [Epidemiological investigation of a family clustering of COVID-19].  Chung-Hua Liu Hsing Ping Hsueh Tsa Chih Chinese Journal of Epidemiology, 41, 629-633. doi:10.3760/cma.j.cn112338-20200223-00152, https://doi.org/10.3760/cma.j.cn112338-20200223-00152 
  16. Guan WD, Chen LP, Ye F, Ye D, Wu SG, Zhou HX, et al. (2020). High-throughput sequencing for confirmation of suspected 2019-nCoV infection identified by fluorescence quantitative polymerase chain reaction.  Chinese Medical Journal, doi:10.1097/CM9.0000000000000792, https://doi.org/10.1097/CM9.0000000000000792   
  17. Hao P, Zhong W, Song S, Fan S & Li X. (2020). Is SARS-CoV-2 originated from laboratory? A rebuttal to the claim of formation via laboratory recombination.  Emerging Microbes & Infections, 9, 545-547. doi:10.1080/22221751.2020.1738279, https://doi.org/10.1080/22221751.2020.1738279 
  18. Hu Z, Song C, Xu C, Jin G, Chen Y, Xu X, et al. (2020). Clinical characteristics of 24 asymptomatic infections with COVID-19 screened among close contacts in Nanjing, China.  Science China. Life sciences, doi:10.1007/s11427-020-1661-4, https://doi.org/10.1007/s11427-020-1661-4 
  19. Hu ZB & Ci C. (2020). 新型冠狀病毒肺炎隱性感染者的發現和管理[Screening and management of asymptomatic infection of corona virus disease 2019 (COVID-19)].  Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine], 54, E025. doi:10.3760/cma.j.cn112150-20200229-00220, https://doi.org/10.3760/cma.j.cn112150-20200229-00220 
  20. Ippolito G, Hui DS, Ntoumi F, Maeurer M & Zumla A. (2020). Toning down the 2019-nCoV media hype-and restoring hope.  The Lancet Respiratory Medicine, 8, 230-231. doi:10.1016/S2213-2600(20)30070-9, https://doi.org/10.1016/S2213-2600(20)30070-9 
  21. Jiang X, Deng L, Zhu Y, Ji H, Tao L, Liu L, et al. (2020). Psychological crisis intervention during the outbreak period of new coronavirus pneumonia from experience in Shanghai.  Psychiatry Research, 286, 112903. doi:10.1016/j.psychres.2020.112903, https://doi.org/10.1016/j.psychres.2020.112903 
  22. Kaplan EH. (2020). Containing 2019-nCoV (Wuhan) coronavirus.  Health Care Management Science, doi:10.1007/s10729-020-09504-6, https://doi.org/10.1007/s10729-020-09504-6 
  23. Kim JM, Chung YS, Jo HJ, Lee NJ, Kim MS, Woo SH, et al. (2020). Identification of Coronavirus Isolated from a Patient in Korea with COVID-19.  Osong Public Health & Research Perspectives, 11, 3-7. doi:10.24171/j.phrp.2020.11.1.02, https://doi.org/10.24171/j.phrp.2020.11.1.02 
  24. Ko WC, Rolain JM, Lee NY, Chen PL, Huang CT, Lee PI, et al. (2020). Arguments in favor of remdesivir for treating SARS-CoV-2 infections.  International Journal of Antimicrobial Agents, 105933. doi:10.1016/j.ijantimicag.2020.105933, https://doi.org/10.1016/j.ijantimicag.2020.105933 
  25. Lee PI, Hu YL, Chen PY, Huang YC & Hsueh PR. (2020). Are children less susceptible to COVID-19?.  Journal of Microbiology, Immunology & Infection, doi:10.1016/j.jmii.2020.02.011, https://doi.org/10.1016/j.jmii.2020.02.011 
  26. Li DKT. (2020). Challenges and responsibilities of family doctors in the new global coronavirus outbreak.  Family Medicine & Community Health, 8, e000333. doi:10.1136/fmch-2020-000333, https://doi.org/10.1136/fmch-2020-000333 
  27. Lu S. (2020). Timely development of vaccines against SARS-CoV-2.  Emerging Microbes & Infections, 9, 542-544. doi:10.1080/22221751.2020.1737580, https://doi.org/10.1080/22221751.2020.1737580 
  28. Luo SH, Liu W, Liu ZJ, Zheng XY, Hong CX, Liu ZR, et al. (2020). A confirmed asymptomatic carrier of 2019 novel coronavirus (SARS-CoV-2).  Chinese Medical Journal, doi:10.1097/CM9.0000000000000798, https://doi.org/10.1097/CM9.0000000000000798 
  29. Marchand-Senecal X, Kozak R, Mubareka S, Salt N, Gubbay JB, Eshaghi A, et al. (2020). Diagnosis and Management of First Case of COVID-19 in Canada: Lessons applied from SARS.  Clinical Infectious Diseases, doi:10.1093/cid/ciaa227, https://doi.org/10.1093/cid/ciaa227 
  30. Maxwell DN, Perl TM & Cutrell JB. (2020). "The Art of War" in the Era of Coronavirus Disease 2019 (COVID-19).  Clinical Infectious Diseases, doi:10.1093/cid/ciaa229, https://doi.org/10.1093/cid/ciaa229 
  31. Namendys-Silva SA. (2020). Respiratory support for patients with COVID-19 infection.  The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30110-7, https://doi.org/10.1016/S2213-2600(20)30110-7 
  32. Porcheddu R, Serra C, Kelvin D, Kelvin N & Rubino S. (2020). Similarity in Case Fatality Rates (CFR) of COVID-19/SARS-COV-2 in Italy and China.  Journal of Infection in Developing Countries, 14, 125-128. doi:10.3855/jidc.12600, https://doi.org/10.3855/jidc.12600 
  33. Qing MX, Li S, Yu S, Ouyang Y, Zeng L, Li X, et al. (2020). Emergency management of the prevention and control of novel coronavirus pneumonia in specialized branches of hospital.  Academic Emergency Medicine, doi:10.1111/acem.13958, https://doi.org/10.1111/acem.13958 
  34. Ren SY, Gao RD & Chen YL. (2020). Fear can be more harmful than the severe acute respiratory syndrome coronavirus 2 in controlling the corona virus disease 2019 epidemic.  World Journal of Clinical Cases, 8, 652-657. doi:10.12998/wjcc.v8.i4.652, https://doi.org/10.12998/wjcc.v8.i4.652 
  35. Ruan ZR, Gong P, Han W, Huang MQ & Han M. (2020). A case of 2019 novel coronavirus infected pneumonia with twice negative 2019-nCoV nucleic acid testing within 8 days.  Chinese Medical Journal, doi:10.1097/CM9.0000000000000788, https://doi.org/10.1097/CM9.0000000000000788 
  36. Tao FB. (2020). 彌合公共衛生與臨床醫學教育裂痕推動醫防融合實踐 [Healing the schism between public health and medicine, promoting the integration of prevention and treatment].  Chung-Hua Yu Fang i Hsueh Tsa Chih [Chinese Journal of Preventive Medicine], 54, E024. doi:10.3760/cma.j.cn112150-20200304-00246, https://doi.org/10.3760/cma.j.cn112150-20200304-00246 
  37. The Lancet. (2020). COVID-19: too little, too late?.  Lancet, 395, 755. doi:10.1016/S0140-6736(20)30522-5, https://doi.org/10.1016/S0140-6736(20)30522-5 
  38. Touret F & de Lamballerie X. (2020). Of chloroquine and COVID-19.  Antiviral Research, 177, 104762. doi:10.1016/j.antiviral.2020.104762, https://doi.org/10.1016/j.antiviral.2020.104762 
  39. Wang J, Zhou M & Liu F. (2020). Exploring the reasons for healthcare workers infected with novel coronavirus disease 2019 (COVID-19) in China.  Journal of Hospital Infection, doi:10.1016/j.jhin.2020.03.002, https://doi.org/10.1016/j.jhin.2020.03.002 
  40. Wilder-Smith A, Chiew CJ & Lee VJ. (2020). Can we contain the COVID-19 outbreak with the same measures as for SARS?.  The Lancet Infectious Diseases, doi:10.1016/S1473-3099(20)30129-8, https://doi.org/10.1016/S1473-3099(20)30129-8 
  41. Xiao Y & Torok ME. (2020). Taking the right measures to control COVID-19.  The Lancet Infectious Diseases, doi:10.1016/S1473-3099(20)30152-3, https://doi.org/10.1016/S1473-3099(20)30152-3 
  42. Yang C, Li C, Wang S & National Clinical Research Center for Child Health and Disorders and Children's Oncology Committee of Chinese Research Hospital Association. (2020). Clinical strategies for treating pediatric cancer during the o utbreak of 2019 novel coronavirus infection.  Pediatric Blood & Cancer, e28248. doi:10.1002/pbc.28248, https://doi.org/10.1002/pbc.28248 
  43. Yang HY, Xu J, Li Y, Liang X, Jin YF, Chen SY, et al. (2020). 新型冠狀病毒肺炎聚集性疫情特徵初步分析 [The preliminary analysis on the characteristics of the cluster for the Corona Virus Disease].  Chung-Hua Liu Hsing Ping Hsueh Tsa Chih Chinese Journal of Epidemiology, 41, 623-628. doi:10.3760/cma.j.cn112338-20200223-00153, https://doi.org/10.3760/cma.j.cn112338-20200223-00153 
  44. Yang XH, Sun RH & Chen DC. (2020).新型冠狀病毒肺炎診治：急性腎損傷不容忽視 [Diagnosis and treatment of COVID-19: acute kidney injury cannot be ignored].  Chung-Hua i Hsueh Tsa Chih [Chinese Medical Journal], 100, E017. doi:10.3760/cma.j.cn112137-20200229-00520, https://doi.org/10.3760/cma.j.cn112137-20200229-00520 
  45. Zeng YM, Xu XL, He XQ, Tang SQ, Li Y, Huang YQ, et al. (2020). Comparative effectiveness and safety of ribavirin plus interferon-alpha, lopinavir/ritonavir plus interferon-alpha and ribavirin plus lopinavir/ritonavir plus interferon-alphain in patients with mild to moderate novel coronavirus pneumonia.  Chinese Medical Journal, doi:10.1097/CM9.0000000000000790, https://doi.org/10.1097/CM9.0000000000000790 
  46. Zhang H, Huang Y & Xie C. (2020). The Treatment and Outcome of a Lung Cancer Patient Infected with SARS-CoV-2.  Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer, doi:10.1016/j.jtho.2020.02.025, https://doi.org/10.1016/j.jtho.2020.02.025 
  47. Zhao S, Cao P, Chong MK, Gao D, Lou Y, Ran J, et al. (2020). The time-varying serial interval of the coronavirus disease (COVID-19) and its gender-specific difference: A data-driven analysis using public surveillance data in Hong Kong and Shenzhen, China from January 10 to February 15, 2020.  Infection Control & Hospital Epidemiology, 1-8. doi:10.1017/ice.2020.64, https://doi.org/10.1017/ice.2020.64 
  48. Zhou YH, Qin YY, Lu YQ, Sun F, Yang S, Harypursat V, et al. (2020). Effectiveness of glucocorticoid therapy in patients with severe novel coronavirus pneumonia: protocol of a randomized controlled trial.  Chinese Medical Journal, doi:10.1097/CM9.0000000000000791, https://doi.org/10.1097/CM9.0000000000000791 



留言

張貼留言